Document is current
Any future updates will be listed below
-
Authors
Yan, Renhong https://orcid.org/0000-0002-7122-6547
Xie, Enjun
Li, Yaning
Li, Jin
Zhang, Yuanyuan
Chi, Ximin https://orcid.org/0000-0002-3839-5998
Hu, Xueping
Xu, Lei
Hou, Tingjun
Stockwell, Brent R.
Min, Junxia https://orcid.org/0000-0001-8099-6327
Zhou, Qiang https://orcid.org/0000-0002-6237-8813
Wang, Fudi https://orcid.org/0000-0001-8730-0003
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (31930057, 31970689, 31971123)
National Key R&D Program of China
China Postdoctoral Science Foundation (2020T130590)
National Key R&D Program of China
- License Information
-
More Information
Article History
Received: 6 July 2021
Accepted: 23 February 2022
First Online: 29 March 2022
Competing interests
: B.R.S. is an inventor on patents and patent applications involving ferroptosis; co-founded and serves as a consultant to Inzen Therapeutics, Nevrox Limited, Exarta Therapeutics, and ProJenX, Inc.; and serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld LLP. The other authors declare no competing interests.
